Suraksha Diagnostic Q1 Results FY27: Date, Revenue Estimates, Key Catalysts and Share Price Target

Suraksha Diagnostic CMP Rs.269. Q1 FY27E revenue Rs.85-98 Cr. PAT estimate Rs.7-9 Cr. 12-month target Rs.322-356.

Updated: 8 Jul 2026 • 1:43 pm

Posted by:

Suraksha Diagnostic Q1 Results FY27: Date, Revenue Estimates, Key Catalysts and Share Price Target

Suraksha Diagnostic Q1 Results FY27 is coming into focus as investors position ahead of the July-August 2026 results season, with Suraksha Diagnostic shares trading at Rs.269 against a market capitalisation of Rs.1,403 Cr and a price-to-earnings multiple of Not meaningful. As a healthcare services name on the NSE and BSE, Suraksha Diagnostic enters the Suraksha Diagnostic Q1 Results FY27 print with the Street watching revenue momentum, margin trajectory and management commentary on FY27 guidance.

This Suraksha Diagnostic Q1 Results FY27 preview is built on a trailing-growth framework applied to the company’s Q1 FY26 base of Rs.74 Cr revenue and Rs.9 Cr net profit, using the most recent year-on-year growth signal from Q4 FY26. This Q1 prediction is a Uniresearch trailing-growth projection, not a formal analyst estimate, and should be read alongside the company’s own guidance once released.

Get Free Investment Predictions and Suraksha Diagnostic Research at Univest

Table of Contents

About Suraksha Diagnostic

Suraksha Diagnostic (NSE: SURAKSHA) operates in the healthcare services space and is tracked on Univest under its NSE and BSE listings. Ahead of the Suraksha Diagnostic Q1 Results FY27 print, the company’s most recent reported quarter (Q4 FY26) shows revenue of Rs.82 Cr and net profit of Rs.6 Cr, forming the base against which the Suraksha Diagnostic Q1 Results FY27 estimates in this article are built. This Suraksha Diagnostic Q1 Results FY27 snapshot is intended as a starting point for research, not a substitute for the company’s own disclosures.

Suraksha Diagnostic Q1 FY27 Estimates

Metric	Q1 FY27E (Range)	Q1 FY26 Actual	YoY Growth
Revenue (Rs. Cr)	85-98	74	+24.7%
Net Profit / PAT (Rs. Cr)	7-9	9	-14.1%
Results Date	July-August 2026 (indicative)
12-Month Target (Uniresearch Estimate)	Rs.322-356

Univest, a SEBI-Registered Investment Advisor, Tracks Suraksha Diagnostic Ahead of Q1 FY27 Results

Key Catalysts to Watch

1. Occupancy and ARPOB Trends

Occupancy and ARPOB improvement across hospital and diagnostic networks is one of the primary variables that analysts are tracking ahead of Suraksha Diagnostic’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Suraksha Diagnostic share price target or faces renewed pressure.

2. Capacity Addition

Capacity addition through new beds or centres supporting medium-term growth is one of the primary variables that analysts are tracking ahead of Suraksha Diagnostic’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Suraksha Diagnostic share price target or faces renewed pressure.

3. Case Mix Improvement

Case mix improvement toward higher-margin specialties aiding profitability is one of the primary variables that analysts are tracking ahead of Suraksha Diagnostic’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Suraksha Diagnostic share price target or faces renewed pressure.

Download the Univest iOS App or Univest Android App to track Suraksha Diagnostic’s live price and Q1 FY27 result updates.

Key Risks to the Suraksha Diagnostic Q1 Results FY27 Outlook

Slower occupancy ramp-up in newly added capacity affecting near-term margins.
Regulatory changes to pricing or insurance reimbursement norms.
Talent cost inflation for specialist doctors and clinical staff.

Q4 FY26 Performance Context for the Suraksha Diagnostic Q1 Results FY27 Print

Suraksha Diagnostic closed Q4 FY26 with revenue of Rs.82 Cr and net profit of Rs.6 Cr, a year-on-year revenue change of +24.7% and PAT change of -14.1% versus Q4 FY25. This base underpins the Suraksha Diagnostic Q1 Results FY27 projection used in this preview and should be read alongside the company’s own Suraksha Diagnostic Q1 Results FY27 commentary once reported.

Technical Analysis Ahead of Suraksha Diagnostic Q1 Results FY27

Suraksha Diagnostic shares last traded at Rs.269. For the current 52-week high and low, support and resistance levels, investors should check the live chart on the Univest app or the NSE website, since these levels move intraday and are not reproduced here to avoid stale data.

Share Price Target Based on the Suraksha Diagnostic Q1 Results FY27 Outlook

3-6 Month Target

Over a 3-6 month horizon, the Suraksha Diagnostic Q1 Results FY27 trailing-growth framework points to a range of Rs.281-303 for Suraksha Diagnostic, contingent on the Suraksha Diagnostic Q1 Results FY27 print matching or beating the trailing growth trend.

12-Month Target

The 12-month target (Uniresearch estimate) tied to this Suraksha Diagnostic Q1 Results FY27 view for Suraksha Diagnostic works out to Rs.322-356, built on the same trailing revenue growth trend and current valuation multiple. Tracking with a constructive bias is how Univest research categorises the stock heading into Suraksha Diagnostic Q1 Results FY27, not a formal Buy or Sell call.

FY27-28 Outlook

Looking out to FY27-28, a sustained continuation of the growth trajectory implied by this Suraksha Diagnostic Q1 Results FY27 analysis would put Suraksha Diagnostic in a Rs.367-415 range, though this is sensitive to sector-wide demand, cost trends and any change in the company’s competitive position.

What to Watch in the Suraksha Diagnostic Q1 Results FY27 Print

Revenue and PAT versus the Suraksha Diagnostic Q1 Results FY27 estimate range in this preview.
Management commentary on FY27 growth guidance and margin trajectory relevant to the Suraksha Diagnostic Q1 Results FY27 narrative.
Occupancy and ARPOB improvement across hospital and diagnostic networks
Slower occupancy ramp-up in newly added capacity affecting near-term margins

Conclusion on Suraksha Diagnostic Q1 Results FY27

Suraksha Diagnostic enters the Q1 FY27 results season trading at Rs.269, with the 12-month Uniresearch target range of Rs.322-356 reflecting a tracking with a constructive bias stance. Investors tracking the Suraksha Diagnostic Q1 Results FY27 print should watch the catalysts and risks above and consult a SEBI-registered advisor before making investment decisions around the results.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

FAQs on Suraksha Diagnostic Q1 Results FY27

When are Suraksha Diagnostic Q1 FY27 results expected?

Ans. Suraksha Diagnostic’s Q1 FY27 results are expected in the July-August 2026 window, in line with the broader NSE and BSE results season for the quarter ending June 2026.

What is the Suraksha Diagnostic Q1 FY27 revenue estimate?

Ans. The Uniresearch trailing-growth estimate for Suraksha Diagnostic’s Q1 FY27 revenue is Rs.85-98 Cr, based on the Q1 FY26 base of Rs.74 Cr.

What is the Suraksha Diagnostic share price target?

Ans. The 12-month Uniresearch estimate for Suraksha Diagnostic share price target is Rs.322-356, based on trailing growth and current valuation multiples.

Is Suraksha Diagnostic a good buy before Q1 FY27 results?

Ans. Suraksha Diagnostic is tracking with a constructive bias heading into Q1 FY27 results. Investors should weigh the catalysts and risks in this article and consult a SEBI-registered advisor before investing.

What should investors watch in Suraksha Diagnostic’s Q1 FY27 results?

Ans. Key items include revenue and PAT versus estimates, management commentary on FY27 guidance, and occupancy and ARPOB improvement across hospital and diagnostic networks.